Home Carboxys 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[5-(carboxymethyl)-4-methyl-2-thiazolyl]thio]methyl]-8-oxo-, (6R,7R)-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[5-(carboxymethyl)-4-methyl-2-thiazolyl]thio]methyl]-8-oxo-, (6R,7R)-

CAS No.:
69739-16-8
Catalog Number:
AG01CCIC
Molecular Formula:
Molecular Weight:
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
25mg
95%
In Stock USA
United States
$72
- +
100mg
95%
In Stock USA
United States
$151
- +
1g
95%
In Stock USA
United States
$364
- +
Product Description
Catalog Number:
AG01CCIC
Chemical Name:
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[[5-(carboxymethyl)-4-methyl-2-thiazolyl]thio]methyl]-8-oxo-, (6R,7R)-
CAS Number:
69739-16-8
MDL Number:
MFCD00864926
IUPAC Name:
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChI:
InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
InChI Key:
XDZKBRJLTGRPSS-BGZQYGJUSA-N
UNII:
Z31298J4HQ
Properties
Complexity:
1030  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
1  
Exact Mass:
584.028g/mol
Formal Charge:
0
Heavy Atom Count:
37  
Hydrogen Bond Acceptor Count:
15  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
584.655g/mol
Monoisotopic Mass:
584.028g/mol
Rotatable Bond Count:
10  
Topological Polar Surface Area:
305A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.2  
Literature
Title Journal
BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems. Journal of pharmacokinetics and pharmacodynamics 20120201
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorganic & medicinal chemistry 20110801
Effects of cefodizime on chemokines of liver tissues in mice with immunological hepatic injury. Chinese medical journal 20110301
Microemulsion and mixed micelle for oral administration as new drug formulations for highly hydrophilic drugs. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100201
Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sexually transmitted infections 20090801
Preparation, physicochemical characterization and biological evaluation of cefodizime metal ion complexes. The Journal of pharmacy and pharmacology 20090601
Inhibitory effects of Cefazolin and Cefodizime on the activity of mushroom tyrosinase. Journal of enzyme inhibition and medicinal chemistry 20090201
Population pharmacokinetics with a very small sample size. Drug metabolism and drug interactions 20090101
Multiple doses of cefodizime are necessary for the treatment of Neisseria gonorrhoeae pharyngeal infection. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20060601
The effects of some antibiotics on polymorphonuclear leukocyte functions of elderly patients in vitro before and after zinc supplementation. International immunopharmacology 20060501
Single-dose pharmacokinetics of cefodizime in critically ill elderly patients. International journal of antimicrobial agents 20060401
Single dose of cefodizime completely eradicated multidrug-resistant strain of Neisseria gonorrhoeae in urethritis and uterine cervicitis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20060401
Selective immediate hypersensitivity to cefodizime. Allergy 20051201
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Journal of pharmaceutical sciences 20050701
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. Journal of medicinal chemistry 20050630
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20050101
[Pharyngeal gonococcal infections]. Nihon Jibiinkoka Gakkai kaiho 20040801
Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models. The Journal of pharmacy and pharmacology 20040401
Immunomodulating effects of cefodizime on Klebsiella pneumoniae-stimulated neutrophils. Immunobiology 20040101
[Gonococcal infection]. Nihon rinsho. Japanese journal of clinical medicine 20030201
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug metabolism and pharmacokinetics 20020101
Outbreak of acute renal failure due to cefodizime-vancomycin association in a heart surgery unit. Intensive care medicine 20011101
In vitro effect of amikacin, imipenem, cefodizime, IFNalpha-2a alone and combinations of antibiotics with IFNalpha-2a on polymorphonuclear leukocyte function in chronic hepatitis patients. Chemotherapy 20010101
Induction of tumor necrosis factor-alpha by cefodizime in U-937 cells. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20010101
Stability of cefodizime disodium in solid state. Acta poloniae pharmaceutica 20010101
Animal models as predictors of outcome of therapy with broad spectrum cephalosporins. The Journal of antimicrobial chemotherapy 19920401
[Acute toxicity study of cefodizime sodium]. The Journal of toxicological sciences 19880601
[Six-month chronic intravenous toxicity study of cefodizime sodium in dogs]. The Journal of toxicological sciences 19880601
[Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration]. The Journal of toxicological sciences 19880601
[Six-month chronic subcutaneous toxicity study of cefodizime sodium in rats]. The Journal of toxicological sciences 19880601
Properties